Highlights

  • Ceretas has commenced its Phase 2 CERE-CALM clinical trial, which enrolled its first patient in October 2026 ahead of the original end-of-year target, evaluating low-intensity focused ultrasound for the behavioural and psychological symptoms of Alzheimer's disease.
  • The company secured full ownership of its core intellectual property during the year and completed Milestone 3 of a government-backed dementia programme, delivering functional prototypes of neuronavigation software and a collaborative lift-assist device.
  • Ceretas entered the period following its ASX listing with approximately A$7.1 million in cash, with its lead CERE-CALM trial fully funded through its planned completion in the first half of calendar 2028.
  • The company is engaging with the US Food and Drug Administration regarding potential approval pathways, including a Pre-Submission request and assessment of eligibility for Breakthrough Device Designation, as it looks to access the large US market.

Ceretas Limited (ASX:CTS) has provided shareholders with a comprehensive letter ahead of its first Annual General Meeting as an ASX-listed company, delivered by its Chief Executive Officer and Managing Director. The letter outlines the clinical, technological and regulatory progress achieved since the company completed an A$8 million initial public offering and listed on the ASX in July 2026. Ceretas is developing a portable, non-invasive therapeutic ultrasound platform intended to treat Alzheimer's disease and other neurodegenerative conditions, drawing on more than a decade of research conducted at The University of Queensland's Queensland Brain Institute. The company's Chief Executive characterised the first period on market as one that demonstrated the team's ability to execute against stated objectives, while acknowledging that significant further clinical validation and regulatory engagement will be required before the technology can achieve its full commercial potential.

CERE-CALM Trial and Clinical Foundations

The most significant development since listing has been the commencement of the CERE-CALM Phase 2 clinical trial. The trial enrolled its first participant in October 2026, ahead of the company's original end-of-year target date, and is designed as a randomised, double-blind, sham-controlled study targeting a minimum of 60 participants across multiple Australian clinical sites. CERE-CALM evaluates the safety and efficacy of low-intensity focused ultrasound in addressing the behavioural and psychological symptoms associated with Alzheimer's disease — including agitation, aggression, anxiety and depression — which the company notes affect the vast majority of patients and place considerable burdens on families, carers and healthcare systems. The trial builds on encouraging Phase 1 results that demonstrated favourable safety outcomes and preliminary signals of benefit in behavioural symptoms, and is designed to provide more rigorous evidence through its controlled methodology. It is fully funded through its planned completion in the first half of calendar 2028, providing clear visibility over the development pathway for investors.

Technology Development and Intellectual Property

Alongside clinical progress, Ceretas has worked to improve the technological and commercial underpinnings of its platform. During the period, the company secured full ownership of its core intellectual property, providing greater control over development and commercialisation decisions. It also successfully completed Milestone 3 of the Australian Government-supported CUREator+ programme, delivering functional prototypes of proprietary image-guided neuronavigation software and a collaborative lift-assist device. These developments form part of the company's next-generation therapeutic ultrasound platform, designed to make treatment delivery more practical, efficient and scalable, potentially enabling single-operator use. This consideration is relevant to the longer-term commercialisation strategy, as the company seeks to develop a technology that can be integrated into broader clinical practice settings beyond specialist facilities. Preclinical research into blood-brain barrier opening is also underway, which could support future applications in targeted drug delivery and potentially provide a pathway to disease-modifying treatment of Alzheimer's.

Regulatory Strategy and Broader Platform Potential

Ceretas has articulated a clear regulatory ambition, with engagement planned with the US Food and Drug Administration to map a potential US approval pathway. This includes a targeted Pre-Submission request and an assessment of eligibility for Breakthrough Device Designation, a status that if granted could meaningfully accelerate the development timeline. Beyond CERE-CALM, the company's technology is being independently evaluated in the AGIFUS Phase 2 trial, funded by a Queensland Health grant, which is assessing different brain targets for treating Alzheimer's-related agitation. The company's longer-term ambition is to establish a commercially viable therapeutic ultrasound platform applicable across Alzheimer's disease and potentially other neurological conditions, with an emphasis on enabling treatment in primary care settings. This would bring the therapy closer to the patient population that needs it most, particularly those who face practical challenges in accessing tertiary specialist facilities. The company's focus on treating patients in lower-acuity, more accessible settings — including potentially primary care environments — reflects an understanding that the Alzheimer's patient population includes many individuals for whom travelling to specialist facilities presents a genuine practical barrier. If the technology can be validated and scaled for broader clinical deployment, it could address not only the clinical unmet need but also the burden on healthcare systems of managing patients with severe behavioural symptoms in high-acuity environments. Achieving this ambition will require navigating a complex regulatory pathway and building clinical evidence across multiple studies, but the company has articulated a thoughtful roadmap for doing so over the medium term.

Key Insights

Ceretas has made a credible start to its life as a listed company, achieving the key milestone of commencing patient enrolment in its Phase 2 CERE-CALM trial ahead of schedule and entering the period with its lead programme fully funded. The combination of a novel non-invasive modality, a compelling unmet need in Alzheimer's behavioural symptoms and a clear regulatory strategy represents the foundation of the Investment case. However, as with all clinical-stage medical technology companies, significant development, regulatory and commercialisation risk remains. The trial's planned completion in 2028 and FDA engagement will be pivotal milestones, and the progression of next-generation device development and blood-brain barrier research adds additional dimensions to the longer-term platform story.